Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care
Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and […]
SPOT-MAS CRC: Expanding Colorectal Cancer Screening Through Blood-Based Methylation Testing
Article Summary: SPOT-MAS CRC is a non-invasive test using blood-based SEPTIN9 gene methylation detection to support screening of early-stage colorectal cancer and advanced precancerous lesions. Achieving a sensitivity of 77.34% for CRC and 54.29% for Pre-Cancerous lesions, alongside a high specificity of 95.95%, SPOT-MAS CRC helps complement traditional screening modalities, empowering proactive cancer prevention. 1. […]
Who May Consider MCED Testing?
Multi-Cancer Early Detection (MCED) testing is an emerging approach that aims to identify signals associated with multiple cancers through a single blood sample. As awareness of MCED grows, some individuals may wonder whether this type of screening could be relevant to them. This article is intended to support general understanding and informed discussion, rather than […]
Cost & Insurance Coverage for MCED Tests in Singapore
This article is for educational purposes only. It does not provide specific pricing, promotions, or purchasing recommendations. Instead, it explains the general cost structure of ctDNA-based MCED tests and current insurance coverage considerations, including why reimbursement remains limited at this stage. In the context of this article, SPOT-MAS (developed by Gene Solutions) is referenced solely as an illustrative example of a […]
The MCED Test experience
The experience with multi-cancer early detection tests offers a closer look at how this approach may be shaping aspects of preventive healthcare. In the context of this MCED article, we focus on the SPOT-MAS test developed by Gene Solutions as one example of a multi-cancer early detection approach. This article outlines the general test process, […]
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on visible or accessible tissue changes. Multi-Cancer Early Detection (MCED) tests — based on a simple blood draw — do not replace these tests but complement […]
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test. This approach is transforming preventive healthcare globally, giving people a better chance for timely treatment and improved outcomes. Let’s explore the guide to Multi-Cancer Early […]
AI and ctDNA Technology: Make Cancer Screening More Accessible and Affordable
Cancer remains a significant health challenge in Asia, accounting for nearly half of the world’s cases. Lung, breast, and colorectal cancers are among the most prevalent, with many patients diagnosed at advanced stages when treatments are less effective and more costly (1). This makes cancer screening not just important—it’s urgent. While current cancer screening methods […]
Top Abstract Poster Winner at 12th Asia-Pacific Breast Cancer Summit 2024
TOP ABSTRACT POSTER WINNER at 12th Asia-Pacific Breast Cancer Summit 2024, in Bali, Indonesia – “Personalized Mutation Tracking in Circulating Tumor DNA Detects Recurrence in High-risk Early Breast Cancer” Congratulations to Gene Solutions R&D division! We are pleased to share that our scientist – Van-Anh Nguyen Hoang. received the Top Abstract Poster Award at the […]
Personalized mutation tracking in circulating tumor dna detects recurrence in high-risk early breast cancer
Our R&D team has yet another poster selected for the APAC Breast Cancer Summit, to be held in March 1 – 3, 2024. If you are attending this meeting – please drop by to hear about our validated studies on monitoring ctDNA for MRD monitoring. Abstract ID: #89 Title: PERSONALIZED MUTATION TRACKING IN CIRCULATING TUMOR […]